TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic…

Details

TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has…

Details

Join TapImmune at Jacksonville’s Immunotherapy Development Program

BioFlorida-Event-April-19-2016 UPCOMING EVENT Jacksonville’s Immunotherapy Development Program The BioFlorida Northeast Chapter – Jacksonville has put together a program at Mayo Clinic focusing on the partnership between the clinic and TapImmune. Join to hear A Clinical Trial Story where representatives both from Mayo Clinic and TapImmune share their journey to date. Mayo will discuss their immunotherapy…

Details

StockNewsNow.com Publishes New SNNLive Video Interview With TapImmune, Inc.

https://tapimmune.com/wp-content/uploads/2016/03/New_SNN_logo.jpg LOS ANGELES, CA–(Posted on Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc. (OTCQB: TPIV), an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, according…

Details

Update with TapImmune, Inc. – Discusses Target Indications, Clinical Development, Milestones and Goals for 2016

LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc. (TPIV), an immuno-oncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, according to the Company’s website…

Details